BioMed X has announced the launch of its first research team at BioMed X France, marking its entry into one of Europe’s fastest-growing life sciences hubs.

The new unit, Team ADB (AI-Empowered Design of Bispecific Antibodies), is based at the XSeed Labs incubator on the R&D campus of Servier in Paris-Saclay, and is hosted at the Spartners facility operated by Servier and BioLabs.

Bispecific antibodies are emerging as a powerful class of biologics, designed to bind two different molecular targets simultaneously. This dual-targeting capability opens new therapeutic pathways in oncology, immunology, and other complex diseases. However, their development remains technically challenging due to structural constraints, unpredictable interactions, and the need to balance stability, specificity, and manufacturability.

The newly formed team is led by Tomabu Adjobimey, an immunologist known for his work in host-pathogen interactions and immune modulation. He currently serves as Associate Professor at the University of Abomey-Calavi in Benin and previously led the Human Immunology Group at the University Hospital Bonn in Germany.

“Our goal is to develop an AI-driven platform that integrates structural modeling, machine learning, and experimental validation to guide the rational design of bispecific antibodies,” said Adjobimey. “This approach could significantly accelerate the discovery of innovative biologic therapeutics addressing major unmet medical needs.”

The France site is led by Paula Wagner Egea, Managing Director and Site Head of BioMed X France, who brings expertise in protein engineering and de novo design. She previously earned her Ph.D. from the Technical University of Munich and has over seven years of international R&D experience.

“The launch of this XSeed Labs team represents an important milestone as we establish our presence in France,” said Wagner Egea. “We are building an interdisciplinary innovation environment at the intersection of AI and biomedical research, and with our partners at Servier, advancing new approaches in immuno-oncology.”

Clément Barjon, Research Project Leader at Servier’s Paris-Saclay R&D institute, highlighted the strategic importance of the collaboration. “Bispecific antibodies are a defining modality in modern oncology, enabling precise immune redirection and multi-pathway targeting. By partnering with BioMed X, we aim to address key engineering challenges that remain largely empirical and difficult to predict,” he said.